---
categories: 
- Database
- Release
date: 2025-06-12
title: Database release
---
Updated current and draft version of the database with FDA oncology approvals from May and June, thus far, 2025.

## Database content updates
Added entries:
- (FDA) Taletrectinib for the treatment of patients with ROS1-positive non-small cell lung cancer.
- (FDA) Telisotuzumab vedotin for the treatment of patients with high c-Met protein overexpression non-squamous non-small cell lung cancer.
- (FDA) Avutometinib in combination with defactinib for the treatment of patients with KRAS-mutant low-grade serous ovarian cancer (G12C, G12V).
